Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda

AIDS Research and Human Retroviruses

Volumn 24, Issue 6, 2008, Pages 889-895

  Ndembi, N ^a   Lyagoba, F ^a   Nanteza, B ^a   Kushemererwa, G ^a   Serwanga, J ^a   Katongole Mbidde, E ^b   Grosskurth, H ^a   Kaleebu, P ^a,b  

^a MRC/UVR1/Uganda Research Unit on AIDS   (Uganda)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH CENTER; HIV DRUG RESISTANCE THRESHOLD SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; METHODOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRUCTURAL GENE; UGANDA; VIRAL GENETICS; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TYPING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC; PREGNANCY; PREVALENCE; RNA, VIRAL; UGANDA;

EID: 45749107886     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0317     Document Type: Article

References (25)

1. WHO/UNAIDS: 3 by 5 progress report. June 2005. WHO/UNAIDS, Geneva, Switzerland.
2. Ministry of Health, Kampala, Republic of Uganda: National HIV drug resistance prevention, monitoring and surveillance plan 2006/07-2010/11, 2006.
3. Bennett DE: The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 2006;19:607-614.
4. Adje C, Cheingsong R, Roels TH, et al.: High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2001;26:501-506.
5. Vergne L, Mabuga-Mouellet G, Mistoul I, et al.: Resistance to antiretroviral treatment in Gabon: Need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002;29(2):165-168.
6. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192:958-966.
7. Shet A, Berry L, Mohri H, et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41(4):439-446.
8. Vergne L, Diagbouga S, Kouanfack C, et al.: HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antiviral Ther 2006;11:575-579.
9. Gale C, Yirrell DL, Campbell E, et al.: Genotypic variation in the pol gene of HIV type 1 in an antiretroviral treatment-naïve population in rural Southwestern Uganda. AIDS Res Hum Retroviruses 2006;10:985-992.
10. Agwale SM, Zeh C, Paxinos E, et al.: Genotypic and phenotypic analysis of human immunodeficiency type 1 in antiretroviral drug-naïve Nigerian patients. AIDS Res Hum Retroviruses 2006;1:22-66.
11. Ndembi N, Abraha A, Pilch H, et al.: Molecular characterization of HIV-1 and HIV-2 in Yaoundé, Cameroon: Evidence of major drug resistance mutations in newly diagnosed non-B patients infected with subtypes other than subtype B. J Clin Microbiol 2008;46(1):101-109.
12. Bertagnolio S and Sutherland D: WHO approach to track HIV drug resistance emergence and transmission in countries scaling up HIV treatment. AIDS 2005;19:1329-1340.
13. Saitou N and Nei M: The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Bio Evol 1987;4:406-425.
14. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotides sequences. J Mol Evol 1980;16:111-120.
15. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1. Top HIV Med 2007; 15(4):119-125.
16. Hirsch MS, Conway B, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. IAS-USA Panel. JAMA 1998;279:2000-2002.
17. Kantor R, Katzenstein DA, Effron B, et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PloS Med 2005;2:325-337.
18. Richard N, Juntilla M, Abraha A, et al.: High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004;20(4):355-364.
19. Herbeck JT, Lyagoba F, Moore SW, et al.: Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. AIDS Res Human Retroviruses 2007;23(5):755-760.
20. Kaleebu P, Nankya I, Yirrell DL, et al.: Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D. J Acquir Immune Syndr 2007;45(1):28-33.
21. Somi G, Kibuka T, Diallo K, et al.: Surveillance of transmitted drug resistance among women attending clinics in Dar es Salaam, Tanzania. Antiviral Ther 2008;13(Suppl 2): 77-82.
22. Abegaz WE, Grossman Z, Wolday D, et al.: Threshold survey evaluating transmittted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 2008;13(Suppl 2):89-94.
23. Pillay V, Ledwaba J, Hunt G, et al.: Antiretroviral drug resistance surveillance among drug-naïve HIV-1 infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antiv Ther 2008;13(Suppl 2);101-107.
24. Bussmann H, de la Hoz Omez F, and Roels TH: Prevalence of transmitted HIV drug resistance in Botswana: Lessons learned from the HIVDR-TS conducted during the 2005 Botswana sentinel survey, 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention 22-25 July 2007, Sydney, Australia (abstract no. TUPEB041).
25. CF Perno, D'Arminio-Monforte A, Cozzi-Lepri A, et al.: 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30-February 2, 2000.